Oppenheimer has upgraded Vertex Pharmaceuticals (VRTX) to an “Outperform” rating with a price target of $540.00 USD. This upgrade follows several other positive analyst revisions for VRTX in early 2026. Vertex Pharmaceuticals is a biotechnology company known for its cystic fibrosis drugs, and it is expanding its portfolio into gene-editing therapies and non-opioid pain medication.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) to Outperform | VRTX Stock News
Oppenheimer has upgraded Vertex Pharmaceuticals (VRTX) to an “Outperform” rating with a price target of $540.00 USD. This upgrade follows several other positive analyst revisions for VRTX in early 2026. Vertex Pharmaceuticals is a biotechnology company known for its cystic fibrosis drugs, and it is expanding its portfolio into gene-editing therapies and non-opioid pain medication.